Hotline: 1800 102 2007
Hotline: 1800 102 2007
Search Business Opportunities
Acquisition 2015-04-02

Dr Reddy’s agrees to acquire UCB business in India for Rs800 crore

One of India’s leading drugmaker companies, Dr Reddy’s Laboratories has announced entering into a definitive agreement to acquire Belgium based pharmaceutical firm UCB for a selected portfolio

Dr Reddy’s agrees to acquire UCB business in India for Rs800 crore

Renowned Indian drugmaker, Dr Reddy's Laboratories, has agreed to enter into a definitive agreement with Belgium based pharmaceutical firm UCB in India to acquire a select portfolio for Rs 800 crore.

Reportedly, in a recent statement released by Dr Reddy said the acquisition is on a slump sale basis and the established products business of UCB would cover the territories of India and neighbouring countries like Nepal, Sri Lanka and Maldives.
The brand has also made it vocal that the transaction includes about 350 employees engaged in operations of UCB's India business and the revenue of the acquired business was approx Rs 150 crore for calendar year 2014.

Significantly, the Indian drugmaker said the acquisition of UCB's existing brand equity in the areas of dermatology, respiratory and paediatrics diseases will further expand Dr Reddy's therapy footprint into these fast growing areas. The transaction is expected to be closed in the first quarter of the financial year 2015-16.
"The acquired UCB portfolio shall accelerate Dr Reddy's presence in the high growth areas of dermatology, respiratory and paediatrics with market leading brands like Atarax, Nootropil, Zyrtec, Xyzal, Xyzal M etc," said Alok Sonig, Senior Vice President and India Business Head.

Meanwhile, Mark McDade, Chief Operating Officer (COO), UCB said, "Finding the right company for our established brands in India was crucial, and Dr. Reddy's knowledge of the local market, combined with their ambitious plans and excellent reputation, convinced us they were the right choice to drive this business forward."

McDade Further added, "This position allows us to enhance our focus on our key neurology portfolio in India, providing innovative solutions to patients living with severe diseases."

Listed on Euronext Brussels, UCB has operations in almost 40 countries across the globe with revenues of 3.3 billion Euros in 2014.

Comment
image
image
image
image
Related opportunities
  • Online learning/E-learning
    About Us: Partnership Opportunity- Franchise partner plays a crucial role in our..
    Locations looking for expansion Maharashtra
    Establishment year 2015
    Franchising Launch Date 2019
    Investment size Rs. 50 K - 2lac
    Space required -NA-
    Franchise Outlets -NA-
    Franchise Type Unit
    Headquater Mumbai Maharashtra
  • About Skoolbag Children take their first step in the world of..
    Locations looking for expansion Uttar pradesh
    Establishment year 2017
    Franchising Launch Date 2019
    Investment size Rs. 5lac - 10lac
    Space required 1000
    Franchise Outlets -NA-
    Franchise Type Unit
    Headquater Noida Uttar pradesh
  • Others Food Service
    About Us: Tempteys is India's first dedicated Cold beverage cafe serving..
    Locations looking for expansion Delhi
    Establishment year 2016
    Franchising Launch Date 2017
    Investment size Rs. 10lac - 20lac
    Space required 300
    Franchise Outlets -NA-
    Franchise Type Unit
    Headquater New delhi Delhi
  • Theme Restaurants
    About Us: Urban Lokal Café is focused on providing a safe..
    Locations looking for expansion Maharashtra
    Establishment year 2017
    Franchising Launch Date 2018
    Investment size Rs. 10lac - 20lac
    Space required 250
    Franchise Outlets -NA-
    Franchise Type Unit
    Headquater Mumbai Maharashtra
Insta-Subscribe to
The Franchising World
Magazine
For hassle free instant subscription, just give your number and email id and our customer care agent will get in touch with you
OR Click here to Subscribe Online
Daily Updates
Submit your email address to receive the latest updates on news & host of opportunities
More Stories

Free Advice - Ask Our Experts